UnknownPhase 1NCT05969977

A First-in-Human Phase 1 Study of Plasmalogen Precursor PPI-1011 in Healthy Adult Volunteers to Assess Safety, Tolerability, and Pharmacokinetics

Studying Chondrodysplasia punctata

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
MED-LIFE DISCOVERIES LP
Principal Investigator
Tara Smith, PhD, MD PhD
MED-LIFE DISCOVERIES LP
Intervention
PPI-1011(drug)
Enrollment
56 enrolled
Eligibility
18-65 years · All sexes
Timeline
2023 – 2023

Study locations (1)

Collaborators

BioPharma Services Inc.

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05969977 on ClinicalTrials.gov

Other trials for Chondrodysplasia punctata

Additional recruiting or active studies for the same condition.

See all trials for Chondrodysplasia punctata →

← Back to all trials